3 Active Pharmaceutical Ingredients Maker, Fluorine Chemicals Maker and Global Pharma Company Stocks With a Strong Future Roadmap: Neuland Laboratories, Navin Fluorine International and Lupin

Drug ingredient, fluorine and pharma stocks let investors follow companies that serve a growing part of the Indian economy. Neuland Laboratories, Navin Fluorine International and Lupin cover an active pharmaceutical ingredients maker, a fluorine chemicals maker and a global pharma company.

This list covers three drug ingredient, fluorine and pharma stocks with complete current figures: Neuland Laboratories, Navin Fluorine International and Lupin. Every figure comes from the latest reported financials and the 29 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Drug Ingredient, Fluorine and Pharma Stocks?

Drug ingredient, fluorine and pharma stocks are listed companies that make drug ingredients for global pharma firms, produce fluorine based specialty chemicals and sell generics and branded medicines in many countries. Their earnings depend on contracts, product mix and approvals.

Drug Ingredient, Fluorine and Pharma Stocks at a Glance

On valuation, Lupin trades at a P/E below the industry P/E, while Neuland Laboratories and Navin Fluorine International trade above it, which reflects the growth the market already expects. Readers comparing drug ingredient, fluorine and pharma stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Drug Ingredient, Fluorine and Pharma Stocks Have a Strong Roadmap in India?

Drug ingredient, fluorine and pharma stocks have a strong roadmap in India because global drug makers adding Indian suppliers, wider use of specialty fluorine products and steady medicine demand keep widening the market for these companies.

• Global supply. Overseas drug makers add Indian partners.
• Specialty chemistry. Fluorine products serve many end uses.
• Medicine demand. Chronic care needs lift steady sales.

Why Neuland Laboratories Features Among These Drug Ingredient, Fluorine and Pharma Stocks

Among the drug ingredient, fluorine and pharma stocks on this list, Neuland Laboratories, based in Hyderabad, makes active pharmaceutical ingredients for generic drugs and runs a custom manufacturing business that supplies innovator companies.

Revenue rose from Rs 953 crore in FY22 to Rs 2,053 crore in FY26, a compound annual growth rate of 21.1%. Net profit grew from Rs 63.8 crore in FY22 to Rs 364 crore in FY26, which works out to a compound annual growth rate of 54.5%.

The company has a return on equity of 19.4%, a debt to equity ratio of 0.16 and a market capitalisation of Rs 24,665 crore. The stock trades at a P/E of 49.5, above the industry P/E of 36.0.

Roadmap: The company is moving up the value chain by growing custom manufacturing, which carries longer contracts and better margins than commodity generic ingredients. A strong order book for development-stage molecules gives visibility on multi-year volumes.

What to watch: Custom manufacturing revenue can move between quarters, so review the full-year trend.

Why Navin Fluorine International Features Among These Drug Ingredient, Fluorine and Pharma Stocks

Among the pharma and chemical shares on this list, Navin Fluorine International is a specialty fluorine chemicals company that makes refrigerant gases, specialty fluorochemicals, and custom research and manufacturing services for pharma and agrochemical clients.

In the June 2026 quarter, revenue grew 46.1% year on year to Rs 1,080 crore, while net profit rose 107.7% to Rs 243 crore. Revenue rose from Rs 1,493 crore in FY22 to Rs 3,379 crore in FY26, a compound annual growth rate of 22.7%.

Net profit grew from Rs 263 crore in FY22 to Rs 664 crore in FY26, which works out to a compound annual growth rate of 26.0%. The company has a return on equity of 16.7%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 41,847 crore. The stock trades at a P/E of 53.0, above the industry P/E of 35.1.

Roadmap: Growth is driven by specialty chemicals, contract manufacturing for global partners and new fluorination capacity. The company has also added capacity for products linked to battery and clean energy applications.

What to watch: Check the ramp-up of new capacity and the share of the contract manufacturing business in revenue.

Why Lupin Features Among These Drug Ingredient, Fluorine and Pharma Stocks

Among the three companies on this list, Lupin is a Mumbai-headquartered global pharmaceutical company with a presence in branded generics in India, complex generics and specialty products in the United States, and active ingredients, with strength in respiratory, cardiovascular, anti-diabetic and anti-infective therapies.

The company has a return on equity of 23.8%, a debt to equity ratio of 0.29 and a market capitalisation of Rs 89,343 crore. The stock trades at a P/E of 16.1, below the industry P/E of 36.0.

Revenue rose from Rs 16,616 crore in FY22 to Rs 29,039 crore in FY26, a compound annual growth rate of 15.0%. Net profit grew from Rs 1,936 crore in FY24 to Rs 5,355 crore in FY26, which works out to a compound annual growth rate of 66.3%. In the June 2026 quarter, revenue grew 32.5% year on year to Rs 8,407 crore, while net profit rose 16.0% to Rs 1,417 crore.

Roadmap: The company is building its pipeline of complex generics, inhalation products and biosimilars, and is widening its specialty portfolio in the United States. Its large Indian branded business and a presence in over 100 markets spread revenue across regions and therapies.

What to watch: Track key launches in the United States, especially in inhalation and complex injectables, and the growth of the India branded business.

Neuland Laboratories vs Navin Fluorine International vs Lupin on Key Financials

The table below sets the three drug ingredient, fluorine and pharma stocks side by side on revenue, profit and margin, using reported figures.

Lupin posts the highest return on equity in this group at 23.8%. Lupin has the largest FY26 revenue at Rs 29,039 crore, and Navin Fluorine International shows the fastest revenue growth with a 22.7% compound annual rate. A useful habit with drug ingredient, fluorine and pharma stocks is to check each new quarterly result against the capacity plans the company described earlier.

Key Risks to Check Before Investing in Drug Ingredient, Fluorine and Pharma Stocks

Every theme carries risks that deserve a check before any decision. For these drug ingredient, fluorine and pharma stocks, the main points are: Long-term pharma and chemical shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Regulatory approvals. Plant inspections and approvals can affect supplies.
• Raw material and energy costs. Input prices can move margins in chemicals.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter drug ingredient, fluorine and pharma stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Drug Ingredient, Fluorine and Pharma Stocks

Drug ingredient, fluorine and pharma stocks reward investors who follow demand trends, order books and margins together. Neuland Laboratories, Navin Fluorine International and Lupin each have a clear plan to grow. Based on the 29 October 2026 close, Neuland Laboratories trades at Rs 19,280, Navin Fluorine International at Rs 8,260.5 and Lupin at Rs 1,989.9. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these drug ingredient, fluorine and pharma stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track drug ingredient, fluorine and pharma stocks, set price alerts and get research-backed stock ideas.

What are drug ingredient, fluorine and pharma stocks?

Ans. Drug ingredient, fluorine and pharma stocks are listed companies that make drug ingredients for global pharma firms, produce fluorine based specialty chemicals and sell generics and branded medicines in many countries. Their earnings depend on contracts, product mix and approvals. This list looks at three of them, Neuland Laboratories, Navin Fluorine International and Lupin, using reported FY22 to FY26 financials and the 29 October 2026 closing prices.

Which drug ingredient, fluorine and pharma stocks are covered in this list?

Ans. This list covers Neuland Laboratories, Navin Fluorine International and Lupin. Based on the 29 October 2026 close, Neuland Laboratories traded at Rs 19,280, Navin Fluorine International at Rs 8,260.5 and Lupin at Rs 1,989.9. Their return on equity ranges from 16.7% to 23.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 15.0% to 22.7%.

Why do drug ingredient, fluorine and pharma stocks have a strong future roadmap in India?

Ans. Drug ingredient, fluorine and pharma stocks have a strong roadmap in India because global drug makers adding Indian suppliers, wider use of specialty fluorine products and steady medicine demand keep widening the market for these companies. The main drivers are as follows. Global supply. Overseas drug makers add Indian partners. Specialty chemistry. Fluorine products serve many end uses. Medicine demand. Chronic care needs lift steady sales. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Neuland Laboratories performed financially?

Ans. Revenue rose from Rs 953 crore in FY22 to Rs 2,053 crore in FY26, a compound annual growth rate of 21.1%. Net profit grew from Rs 63.8 crore in FY22 to Rs 364 crore in FY26, which works out to a compound annual growth rate of 54.5%. The company has a return on equity of 19.4%, a debt to equity ratio of 0.16 and a market capitalisation of Rs 24,665 crore. The stock trades at a P/E of 49.5, above the industry P/E of 36.0. Looking ahead, the company is moving up the value chain by growing custom manufacturing, which carries longer contracts and better margins than commodity generic ingredients. A strong order book for development-stage molecules gives visibility on multi-year volumes.

How has Navin Fluorine International performed financially?

Ans. Revenue rose from Rs 1,493 crore in FY22 to Rs 3,379 crore in FY26, a compound annual growth rate of 22.7%. Net profit grew from Rs 263 crore in FY22 to Rs 664 crore in FY26, which works out to a compound annual growth rate of 26.0%. In the June 2026 quarter, revenue grew 46.1% year on year to Rs 1,080 crore, while net profit rose 107.7% to Rs 243 crore. The company has a return on equity of 16.7%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 41,847 crore. The stock trades at a P/E of 53.0, above the industry P/E of 35.1. Looking ahead, growth is driven by specialty chemicals, contract manufacturing for global partners and new fluorination capacity. The company has also added capacity for products linked to battery and clean energy applications.

How has Lupin performed financially?

Ans. Revenue rose from Rs 16,616 crore in FY22 to Rs 29,039 crore in FY26, a compound annual growth rate of 15.0%. Net profit grew from Rs 1,936 crore in FY24 to Rs 5,355 crore in FY26, which works out to a compound annual growth rate of 66.3%. In the June 2026 quarter, revenue grew 32.5% year on year to Rs 8,407 crore, while net profit rose 16.0% to Rs 1,417 crore. The company has a return on equity of 23.8%, a debt to equity ratio of 0.29 and a market capitalisation of Rs 89,343 crore. The stock trades at a P/E of 16.1, below the industry P/E of 36.0. Looking ahead, the company is building its pipeline of complex generics, inhalation products and biosimilars, and is widening its specialty portfolio in the United States. Its large Indian branded business and a presence in over 100 markets spread revenue across regions and therapies.

What risks should investors check before buying drug ingredient, fluorine and pharma stocks?

Ans. Investors should check a few risks before buying drug ingredient, fluorine and pharma stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Raw material and energy costs. Input prices can move margins in chemicals. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of drug ingredient, fluorine and pharma stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 29 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.